PMID- 23574159 OWN - NLM STAT- MEDLINE DCOM- 20140218 LR - 20240321 IS - 1996-3181 (Electronic) IS - 1871-5273 (Print) IS - 1871-5273 (Linking) VI - 12 IP - 4 DP - 2013 Jun TI - N-3 (omega-3) polyunsaturated Fatty acids in the pathophysiology and treatment of depression: pre-clinical evidence. PG - 450-9 AB - A growing literature suggests the association of low tissue levels and/or dietary intake of n-polyunsaturated fatty acids (PUFA) with depressive illnesses. Animal studies show that low tissue and/or dietary n-3 PUFAs can lead to behaviors and neurobiological effects associated with depression and can potentiate the consequences of stress, whereas higher levels have the opposite effect. These data support the involvement of n-3 PUFAs levels in the disease processes underlying depression. In addition, these pre-clinical findings indicate neurobiological mechanisms whereby n-3 PUFAs may contribute to the disease including control of serotonergic and dopaminergic function, modulation of brain-derived neurotrophic factor (BDNF) in the hippocampus, regulation of the hypothalamic-pituitary-adrenal axis, and effects on neuroinflammation. This evidence for a role for n-3 PUFA in the pathophysiology and treatment of depressive illness are reviewed. The implications of these finding for future pre-clinical research and clinical application are discussed. FAU - Levant, Beth AU - Levant B AD - Department of Pharmacology, University of Kansas Medical Center, MS-1018, 3901 Rainbow Blvd., Kansas City, KS 66160, USA. blevant@kumc.edu LA - eng GR - P20 RR016475/RR/NCRR NIH HHS/United States GR - NIH R01MH071599/MH/NIMH NIH HHS/United States GR - P30 HD02528/HD/NICHD NIH HHS/United States GR - R01 MH071599/MH/NIMH NIH HHS/United States GR - P30 HD002528/HD/NICHD NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Review PL - United Arab Emirates TA - CNS Neurol Disord Drug Targets JT - CNS & neurological disorders drug targets JID - 101269155 RN - 0 (Fatty Acids, Omega-3) SB - IM MH - Animals MH - Brain/drug effects/physiopathology MH - Depression/*diet therapy/*physiopathology MH - Disease Models, Animal MH - *Drug Evaluation, Preclinical MH - Fatty Acids, Omega-3/*therapeutic use MH - Humans PMC - PMC4115447 MID - NIHMS591662 COIS- CONFLICT OF INTEREST The author confirms that this article content has no conflict of interest. EDAT- 2013/04/12 06:00 MHDA- 2014/02/19 06:00 PMCR- 2014/07/30 CRDT- 2013/04/12 06:00 PHST- 2013/01/22 00:00 [received] PHST- 2013/03/19 00:00 [revised] PHST- 2013/03/22 00:00 [accepted] PHST- 2013/04/12 06:00 [entrez] PHST- 2013/04/12 06:00 [pubmed] PHST- 2014/02/19 06:00 [medline] PHST- 2014/07/30 00:00 [pmc-release] AID - CDTCNSND-EPUB-20130404-6 [pii] AID - 10.2174/1871527311312040003 [doi] PST - ppublish SO - CNS Neurol Disord Drug Targets. 2013 Jun;12(4):450-9. doi: 10.2174/1871527311312040003.